Ideal Cures has expanded its drug delivery tech portfolio with a new alginic acid-based, delayed-release coating that – it claims – has advantages over shellac and starch.
Tamarisk Technologies is in licensing talks with several Big Pharmas over a tech which it claims could solve the oral insulin puzzle and “turn the industry upside down”.
Formac Pharmaceuticals and WR Grace say their silica platform can improve the formulation selection process for poorly soluble APIs (active pharmaceutical ingredients).
Nano Terra, a surface engineering and nanotechnology company based in Brighton Massachusetts, US, has struck a deal to acquire neighbouring drug developer, Surface Logix.
Pfizer’s Capsugel unit has bought an injection molding technology that, it believes, will expand its capsule filling business into new “high value segments.”
NextPharma Technologies will be bought by Sun European Partners, the European adviser to US investment group Sun Capital Partners, in a deal announced late yesterday.
Pharma should forget about ‘the next blockbuster drug’ and invest more money creating novel drug delivery systems with emerging developers to enhance product value and efficacy, say researchers.
Demand for high-end capsule filling technologies, particularly those used for early clinical development projects, has increased in 2010 according to Capsugel.
Penn Pharma and Xcelience have formed an Xcelodose-focused joint venture to meet client demand in Europe and Asia for powder-in-capsule (PIC) services.
ISP Pharmaceuticals has expanded its extrusion spheronisation offering with the installation of new dedicated technology at its laboratory in Sao Paulo, Brazil.
DPT Laboratories has added bulk production and packaging capacity at its liquid and semi-solids plant in San Antonio, Texas in a continuation of its recent manufacturing reorganisation.
New specialist development and manufacturing “centres of excellence” increase efficiencies and customer access to expertise, DPT Laboratories spokesman tells Outsourcing-pharma.
Patheon attributes Q1 loss to charges and plant closure costs and says there has been “an encouraging increase in new sales activity” in calendar 2010.
German contract manufacturing organisation (CMO) Excella will provide pneumatic dry granulation (PDG) tablet making services through a new partnership with Finnish specialty pharmaceutical firm Atacama Labs.
Almac Pharma Services has bolstered its product development offering with a new Xcelodose 600s precision powder micro-dosing system that, it claims, can cut processing time, API usage and costs.
Indian CRO Ankur Drugs and Pharma is a step closer to stating production of Romaco’s Siebler StripTabs now the German firm developed a fully integrated manufacturing line.
Dutch contract delivery services firm OctoPlus says it will cut 35 jobs as part of ongoing efforts to boost efficiency, improve competitiveness and broaden its client base and revenue streams.
Dalton Pharma Services has rolled out a new formulation development service that completes the firm’s contract drug manufacturing offering according to CEO Peter Pekos.
With Lonza and JLL competing over Patheon Outsourcing-Pharma looks at what the CMO offers to a prospective buyer, analysing its global manufacturing capacity and backlog using interactive maps and graphs.
CMO Encap has expanded its colonic delivery offering and is combining the technology with liquid dosage forms to provide clients with a way to administer a wide range of therapeutics to the region.
Sweden’s XSpray Microparticles says its new particle plant proves its RightSize tech can be scaled-up for industrial applications and will be a boost for its contract services offering.
Portuguese contract manufacturing organisation (CMO) Hovione plans to invest €2m ($3m) in a new R&D unit in the capital Lisbon, as expansion space at its active pharmaceutical ingredient (API) plant in Loures is limited.
Sinobiopharma is seeking a Chinese patent covering the manufacture of capsule forms of the heart drug perindopril, claiming it is the first company in the world to produce the medication in this easy to swallow format.
Cost cutting has sustained pharma profits in the faltering global economy, however top executives are starting to realise that reducing R&D capacity may not have been the smartest move in an era of weak pipelines and impending patent expiry, according...
Irish drugmaker Elan has shelved plans to sell its contracting arm EDT in favour of improving the division’s profitability, despite receiving what it describes as “considerable interest” in the unit.
Pfizer is shifting its research focus to those diseases where its sees the potential for the biggest treatment improvements and profits, while dropping eight disease areas including cholesterol.
Irish drugmaker Elan is considering a separate stock exchange
listing for its contract services unit, Elan Drug Technology,
according to comments by executives at its recent annual general
meeting.
GVK Bio has reinforced its claim to be India's top contract
research organisation with a 100-crore ($25m) push from a private
investment company. The funds will be used to expand its drug
discovery services and push further into...
New research from Frost & Sullivan provides a snapshot of
biopharma spending trends on contract research organisations
(CROs), along with forecasts for industry growth.
The Enterion capsule is quickly becoming big pharma's new best
friend as the technology helps drug companies assess the
feasibility of oral modified release formulations.
Crosslinking is a natural phenomenon occurring in gelatin that negatively impacts soft capsules, reducing their stability and prolonging their dissolution...
New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...
Invivo: Many orally dosed APIs are bioavailable only when formulated as an enteric dosage form to protect them from the harsh environment of the stomach....
